If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory service entitled Alzheimer’s Disease, Decision Resources is offering an exclusive analyst call entitled Potential Blockbuster Derailed: Eli Lilly Discontinues Development of Semagacestat for Alzheimer’s Disease. Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. Eli Lilly has discontinued development of semagacestat after the agent proved to be worse than placebo in two Phase III clinical trials for Alzheimer’s disease. Preliminary analyses of the ongoing IDENTITY (Interrupting Alzheimer’s Dementia by Evaluating Treatment of Amyloid Pathology) and IDENTITY-2 trials showed that semagacestat, an oral small molecule gamma-secretase inhibitor, did not slow disease progression in mild to moderate Alzheimer’s disease patients. Instead, the trials showed that treatment with the drug resulted in worsened cognition and function when compared with placebo as well as carrying an increased risk of melanoma. As a result, Eli Lilly has suspended further development of semagacestat, although this decision does not affect ongoing development of the company’s other Alzheimer’s disease therapy—the anti-beta-amyloid monoclonal antibody solanezumab. Based on the enthusiasm of interviewed experts for the drug’s mechanism of action and its Phase II safety and tolerability data, Decision Resources had previously forecasted that semagacestat would attain blockbuster sales in 2019 in the Alzheimer’s disease drug market. Following the discontinuation of semagacestat, Decision Resources has updated its Alzheimer’s Disease Pharmacor advisory service and market forecast. This 15-minute analyst call, presented by Decision Resources Analyst Georgiana L. Kuhlmann, M.Sc., will answer the following questions:
Ms. Kuhlmann will conduct a live Q&A session after the presentation. Registration Potential Blockbuster Derailed: Eli Lilly Discontinues Development of Semagacestat for Alzheimer’s Disease September 8, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-993-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Georgiana L. Kuhlmann, M.Sc., is an analyst in the Central Nervous System Disorders Group at Decision Resources, where she has co-authored market research reports on Alzheimer’s disease, bipolar disorder and acute ischemic stroke. Prior to joining Decision Resources, Ms. Kuhlmann conducted both basic and translational cancer research at the Massachusetts Institute of Technology, Massachusetts General Hospital and Wesleyan University. Ms. Kuhlmann holds a Master of Science in Biology from MIT and a B.A. in Molecular Biology and Biochemistry and Italian Studies from Wesleyan University.